A Peek Under the Hood: Explaining the MiniMedTM 780G Algorithm with Meal Detection Technology

Benyamin Grosman; Anirban Roy; Louis Lintereur; Kamuran Turksoy; Andrea Benedetti; Toni L. Cordero; Robert A. Vigersky; Jennifer McVean; Andrew S. Rhinehart; Ohad Cohen

doi:10.1089/dia.2023.0446

A Peek Under the Hood: Explaining the MiniMed^TM 780G Algorithm with Meal Detection Technology

Benyamin Grosman^*, Anirban Roy, Louis Lintereur, Kamuran Turksoy, Andrea Benedetti, Toni L. Cordero, Robert A. Vigersky, Jennifer McVean, Andrew S. Rhinehart, Ohad Cohen

^*Corresponding author for this work

Medtronic, Inc.

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

The MiniMed™ 780G system (780G) received Conformité Européenne mark in June 2020 and was, recently, approved by the U.S. Food and Drug Administration (April 2023). Clinical trials and real-world analyses have demonstrated MiniMed™ 780G system safety and effectiveness and that glycemic outcomes (i.e., time in range) improve with recommended settings use. In this publication, we will explain the iterative development of the 780G algorithm and how this technology has simplified diabetes management.

Original language	English
Pages (from-to)	17-23
Number of pages	7
Journal	Diabetes Technology and Therapeutics
Volume	26
DOIs	https://doi.org/10.1089/dia.2023.0446
State	Published - 1 Mar 2024
Externally published	Yes

Keywords

Adaptive control
Advanced hybrid closed loop
Algorithm
Artificial pancreas
Automated insulin delivery
Type 1 diabetes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/dia.2023.0446

Cite this

@article{ee506d4f6cc34069b63248289eb9fa30,

title = "A Peek Under the Hood: Explaining the MiniMedTM 780G Algorithm with Meal Detection Technology",

abstract = "The MiniMed{\texttrademark} 780G system (780G) received Conformit{\'e} Europ{\'e}enne mark in June 2020 and was, recently, approved by the U.S. Food and Drug Administration (April 2023). Clinical trials and real-world analyses have demonstrated MiniMed{\texttrademark} 780G system safety and effectiveness and that glycemic outcomes (i.e., time in range) improve with recommended settings use. In this publication, we will explain the iterative development of the 780G algorithm and how this technology has simplified diabetes management.",

keywords = "Adaptive control, Advanced hybrid closed loop, Algorithm, Artificial pancreas, Automated insulin delivery, Type 1 diabetes",

author = "Benyamin Grosman and Anirban Roy and Louis Lintereur and Kamuran Turksoy and Andrea Benedetti and Cordero, {Toni L.} and Vigersky, {Robert A.} and Jennifer McVean and Rhinehart, {Andrew S.} and Ohad Cohen",

note = "Publisher Copyright: {\textcopyright} Mary Ann Liebert, Inc.",

year = "2024",

month = mar,

day = "1",

doi = "10.1089/dia.2023.0446",

language = "אנגלית",

volume = "26",

pages = "17--23",

journal = "Diabetes Technology and Therapeutics",

issn = "1520-9156",

publisher = "Mary Ann Liebert Inc.",

}

TY - JOUR

T1 - A Peek Under the Hood

T2 - Explaining the MiniMedTM 780G Algorithm with Meal Detection Technology

AU - Grosman, Benyamin

AU - Roy, Anirban

AU - Lintereur, Louis

AU - Turksoy, Kamuran

AU - Benedetti, Andrea

AU - Cordero, Toni L.

AU - Vigersky, Robert A.

AU - McVean, Jennifer

AU - Rhinehart, Andrew S.

AU - Cohen, Ohad

N1 - Publisher Copyright: © Mary Ann Liebert, Inc.

PY - 2024/3/1

Y1 - 2024/3/1

N2 - The MiniMed™ 780G system (780G) received Conformité Européenne mark in June 2020 and was, recently, approved by the U.S. Food and Drug Administration (April 2023). Clinical trials and real-world analyses have demonstrated MiniMed™ 780G system safety and effectiveness and that glycemic outcomes (i.e., time in range) improve with recommended settings use. In this publication, we will explain the iterative development of the 780G algorithm and how this technology has simplified diabetes management.

AB - The MiniMed™ 780G system (780G) received Conformité Européenne mark in June 2020 and was, recently, approved by the U.S. Food and Drug Administration (April 2023). Clinical trials and real-world analyses have demonstrated MiniMed™ 780G system safety and effectiveness and that glycemic outcomes (i.e., time in range) improve with recommended settings use. In this publication, we will explain the iterative development of the 780G algorithm and how this technology has simplified diabetes management.

KW - Adaptive control

KW - Advanced hybrid closed loop

KW - Algorithm

KW - Artificial pancreas

KW - Automated insulin delivery

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85185709027&partnerID=8YFLogxK

U2 - 10.1089/dia.2023.0446

DO - 10.1089/dia.2023.0446

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 38377324

AN - SCOPUS:85185709027

SN - 1520-9156

VL - 26

SP - 17

EP - 23

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

ER -